Unknown

Dataset Information

0

Weekly versus tri?weekly paclitaxel with carboplatin for first?line treatment in women with ovarian cancer

ABSTRACT: Abstract This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness and safety of weekly paclitaxel with that of three?weekly paclitaxel, in combination with carboplatin, as first?line chemotherapy treatment for ovarian cancer.

SUBMITTER: Syn N 

PROVIDER: S-EPMC6457624 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
| S-EPMC5081077 | biostudies-literature
Unknown Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
| S-EPMC4682258 | biostudies-literature
Unknown Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
| S-EPMC3446254 | biostudies-literature
Unknown nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
| S-EPMC6096741 | biostudies-literature
Unknown Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.
| S-EPMC4067944 | biostudies-literature
Unknown Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
| S-EPMC8663341 | biostudies-literature
Unknown Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
| S-EPMC5665762 | biostudies-literature
Unknown Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.
| S-EPMC5955142 | biostudies-other
Unknown Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
| S-EPMC8637468 | biostudies-literature
Unknown A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
| S-EPMC7078205 | biostudies-literature